CTOR citiusonc.com Company Cash on Hand

Brandmark of Citius Oncology (CTOR)

What are the growth horizons for Citius Oncology, Inc. (CTOR) amid strict FDA control over therapy costs? The high authority of the developer of targeted drugs for leukemia confirms the potential, while changes in cash holdings demonstrate the actual volume of reserves. Meanwhile, the level of 0.02 reflects the current magnitude of liquidity. Ultimately, the integration of Lymphir into lymphoma treatment protocols solidifies the company's status as a key player in the orphan drug niche.

Company Cash Reserve: Citius Oncology, Inc (CTOR) for 08/14/2024 - 11/21/2026

Metric breakdowns and analytics for Citius Oncology Inc. (CTOR)

- stock value and consensus price forecast:
Analysis of all company metrics:CTOR Citius Oncology, Inc.
Brand item of Citius Oncology

This indicator reflects the current liquidity of the issuer, serving as a measure of its ability to fund operating activities without external borrowing. By analyzing the size of cash resources, an investor assesses the burn rate and the company's independence from credit markets. The metric aggregates all cash and equivalents, determining the financial stability of the business. For Citius Oncology, Inc. (CTOR), this is critical, as the commercialization of the drug requires expenditures in the absence of major manufacturing assets.

Competing companies

Company Cash Volume ONC|HALO - Company Cash Reserve|Revolution Medicines - Company Cash on Hand|Company Cash Volume Ascentage Pharma AAPG|CGON - Company Cash Funds|Company Total Cash Volume URGN|BCAX: Company Cash Volume|PSNL - Company Liquid Assets|ERAS (Erasca Inc) - Company Cash Volume|Company Cash Reserve Delcath Systems Inc DCTH|Company Cash Funds YmAbs (YMAB)|Company Liquid Assets Aura Bio|Company Cash Volume CADL (Candel Therapeutics Inc.)|accuray.com (ARAY) - Company Cash Reserve|SELLAS Life Sciences Group - Company Cash Volume|ACTU - Company Cash Volume|HURA: Company Cash Volume|Company Total Cash Volume TARA (Protara)|FATE (fatetherapeutics.com) - Company Cash Volume|Company Cash Reserve Aadi Bioscience WHWK|Company Cash Volume TCRX|CSBR - Company Cash Reserve|XBiotech - Company Cash on Hand|CEL-SCI Corporation (CVM) - Company Cash Reserve|OSTX - Company Cash Funds|Company Cash Reserve Radiopharm Theranostics Ltd|ARTV (artivabio.com) - Company Cash on Hand|ANL (Adlai Nortye Ltd) - Company Cash Funds|Company Cash on Hand VERU|Tempest Therapeutics (TPST) - Company Liquid Assets|Company Cash Volume XLO|Company Cash on Hand Renovaro RENB|Company Cash Volume MURA (Mural Oncology PLC)|KAPA - Company Cash on Hand|OnKure Therapeutics - Company Cash Volume|w2.cytomed.sg - Company Total Cash Amount|Curis Corp (CRIS) - Company Cash Funds|Company Cash Reserve Apollomics Corp (APLM)|Company Cash Funds Tharimmune|Company Cash Volume advanbiomed.com|Company Cash Funds Genprex, Inc (GNPX)|Company Liquid Assets Calidi Biotherapeutics, Inc.|Company Cash Volume SBFM (Sunshine Biopharma Inc.)|XBIO - Company Cash on Hand|SLRX: Company Cash on Hand|Company Cash Balance PPBT (Purple Biotech Ltd.)|AONC: Company Cash Volume|Company Cash Reserve BeOne Medicines (BGNE)|Company Cash Funds Checkpoint Therapeutics, Inc.|Company Cash on Hand Elevation Oncology (ELEV)|Company Cash Funds iCAD Corp (ICAD)|Company Cash on Hand Ikena IKNA|Company Cash Volume NTBL (notablelabs.com)|VIRX - Company Cash on Hand|MOR: Company Cash on Hand|NAYA - Company Cash Volume|Ascentage Pharma (AAPGV) - Company Cash Funds